cCAM Biotherapeutics develops novel immunotherapies for cancer. cCAM’s lead agent, CM-24, is an immunomodulatory antibody that blocks a novel immune checkpoint, thereby harnessing the patient’s immune system to attack tumors. In July 2015, the company was acquired by Merck.
Field:BioPharma
Status:Acquired by Merck
Location: Israel
Investors 1
| Date | Name | Website |
| - | Pontifax V... | pontifax.c... |
Mentions in press and media 2
| Date | Title | Description | Source |
| 15.12.2015 | Healthcare venture firm OrbiMed launching $300M Israeli inve... | Globes viewed an OrbiMed presentation which, last April, appeared to be in preparation for the secon... | medcitynew... |
| - | Healthcare venture firm OrbiMed launching $300M Israeli inve... | Life sciences venture firm OrbiMed Advisors is raising capital for a $300 million investment fund ba... | medcitynew... |